Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,612.40
(
0.11%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
101.17
(
0.00%
)
Bitcoin
77,392.31
(
0.49%
)
News Focus
News Focus
Post# of 257624
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123010
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 83521

Sunday, 09/13/2009 11:12:55 PM

Sunday, September 13, 2009 11:12:55 PM

Post# of 257624
MNTA:

You're assuming no one else will ever be able to launch a generic lovenox. What makes you think Teva is the type of company to give up? If Sanofi is going to lose a massive market share, why wouldn't they launch an AG?

???

The calculation in question is for the best-case scenario, and the assumptions you're referring to are the definition of the best case.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today